학술논문

Usp16 contributes to somatic stem-cell defects in Down’s syndrome
Document Type
article
Source
Nature. 501(7467)
Subject
Biochemistry and Cell Biology
Biomedical and Clinical Sciences
Biological Sciences
Genetics
Stem Cell Research
Intellectual and Developmental Disabilities (IDD)
Down Syndrome
Stem Cell Research - Nonembryonic - Non-Human
Brain Disorders
1.1 Normal biological development and functioning
Aetiology
Underpinning research
2.1 Biological and endogenous factors
Adult Stem Cells
Animals
Cell Proliferation
Cellular Senescence
Chromosomes
Human
Pair 21
Cyclin-Dependent Kinase Inhibitor p16
Disease Models
Animal
Epithelium
Female
Fibroblasts
Gene Dosage
Gene Expression Regulation
Hematopoietic Stem Cells
Humans
Mammary Glands
Animal
Mice
Molecular Targeted Therapy
Neural Stem Cells
Trisomy
Ubiquitin Thiolesterase
Ubiquitination
General Science & Technology
Language
Abstract
Down's syndrome results from full or partial trisomy of chromosome 21. However, the consequences of the underlying gene-dosage imbalance on adult tissues remain poorly understood. Here we show that in Ts65Dn mice, which are trisomic for 132 genes homologous to genes on human chromosome 21, triplication of Usp16 reduces the self-renewal of haematopoietic stem cells and the expansion of mammary epithelial cells, neural progenitors and fibroblasts. In addition, Usp16 is associated with decreased ubiquitination of Cdkn2a and accelerated senescence in Ts65Dn fibroblasts. Usp16 can remove ubiquitin from histone H2A on lysine 119, a critical mark for the maintenance of multiple somatic tissues. Downregulation of Usp16, either by mutation of a single normal Usp16 allele or by short interfering RNAs, largely rescues all of these defects. Furthermore, in human tissues overexpression of USP16 reduces the expansion of normal fibroblasts and postnatal neural progenitors, whereas downregulation of USP16 partially rescues the proliferation defects of Down's syndrome fibroblasts. Taken together, these results suggest that USP16 has an important role in antagonizing the self-renewal and/or senescence pathways in Down's syndrome and could serve as an attractive target to ameliorate some of the associated pathologies.